Palbociclib
Showing 26 - 50 of 348
Renal Cell Carcinoma Trial in Macquarie University, Haifa (Belzutifan, Palbociclib)
Recruiting
- Renal Cell Carcinoma
- Belzutifan
- Palbociclib
-
Macquarie University, New South Wales, Australia
- +1 more
Aug 15, 2022
Advanced Clear Cell Renal Cell Carcinoma Trial in Boston (Axitinib, Palbociclib, Avelumab)
Not yet recruiting
- Advanced Clear Cell Renal Cell Carcinoma
- Axitinib
- +2 more
-
Boston, Massachusetts
- +2 more
Jun 27, 2022
Inhibition of Autophagy Synergizes Anti-tumor Effect Trial in Guangzhou (100mg bid dose of hydroxychloroquine combined with
Recruiting
- Inhibition of Autophagy Synergizes Anti-tumor Effect
- 100mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
- RP2D dose of 100mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
-
Guangzhou, Guangdong, ChinaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jul 19, 2023
Breast Cancer Female Trial in Belgium (Palbociclib)
Completed
- Breast Cancer Female
- Palbociclib
-
Anderlecht, Belgium
- +4 more
Jun 23, 2022
Advanced Clear Cell Renal Carcinoma (Ccrcc), Papillary Renal Cell Carcinoma (Prcc) Trial run by the National Cancer Institute
Not yet recruiting
- Advanced Clear Cell Renal Carcinoma (Ccrcc)
- Papillary Renal Cell Carcinoma (Prcc)
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Feb 2, 2023
Palbociclib in Combination With an Aromatase Inhibitor
Recruiting
- Metastatic Breast Cancer
- Palbociclib + an aromatase inhibitor
- Aromatase inhibitor
-
New York, New York10017
May 2, 2022
Real-world Prescription Pattern of Palbociclib Combination
Active, not recruiting
- Metastatic Breast Cancer
- Patients who received Palbociclib as first line therapy in MBC setting
-
Seoul, Korea, Republic ofPfizer Local Country Office
Jun 28, 2022
Among Brazil Receiving Palbociclib Combinations for HR+/HER2-
Recruiting
- Breast Cancer
- Breast Carcinoma
-
Brasilia, Distrito Federal, BrazilInstituto D´Or de Pesquisa E Ensino - Brasília
Aug 15, 2022
Breast Cancer Trial in Shanghai (Chidamide, Abemaciclib, Fulvestrant)
Recruiting
- Breast Cancer
- Chidamide
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jul 31, 2022
Lung Cancer Squamous Cell, Solid Tumors, Head & Neck Cancer Trial in Boston (Palbociclib, Gedatolisib)
Recruiting
- Lung Cancer Squamous Cell
- +3 more
- Palbociclib
- Gedatolisib
-
Boston, Massachusetts
- +2 more
Jan 9, 2023
Breast Tumor Female, Quality of Life Trial in São Paulo (Use of the WeCancer app combined with the smartwatch.)
Recruiting
- Breast Neoplasm Female
- Quality of Life
- Use of the WeCancer app combined with the smartwatch.
-
São Paulo, Brazil
- +1 more
Aug 8, 2022
Breast Cancer, Breast Carcinoma, Cancer of Breast Trial in Saint Louis, Lincoln (Palbociclib, Letrozole, Fulvestrant)
Active, not recruiting
- Breast Cancer
- +3 more
- Palbociclib
- +7 more
-
Saint Louis, Missouri
- +1 more
Jul 20, 2022
Malignant Solid Tumor, Ovarian Low Grade Serous Adenocarcinoma, Pancreatic Carcinoma Trial (Binimetinib, Biopsy, Biospecimen
Not yet recruiting
- Malignant Solid Neoplasm
- +4 more
- Binimetinib
- +6 more
- (no location specified)
Nov 8, 2022
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (drug, radiation, procedure)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Palbociclib
- +5 more
-
Saint Louis, MissouriWashington University School of Medicine
Feb 25, 2022
Overall Survival in Japanese HR+/HER2- Advanced Breast Cancer
Active, not recruiting
- Breast Cancer
- palbociclib plus letrozole
-
Chiba-shi, Chiba, Japan
- +12 more
Dec 15, 2022
Breast Tumor Female Trial in Melbourne (Venetoclax, Palbociclib, Letrozole)
Recruiting
- Breast Neoplasm Female
- Venetoclax
- +2 more
-
Melbourne, Victoria, Australia
- +2 more
Mar 10, 2022
Malignant Female Reproductive System Tumor, Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Tumor Trial
Not yet recruiting
- Malignant Female Reproductive System Neoplasm
- +3 more
- Biopsy
- +7 more
- (no location specified)
Nov 9, 2023
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv Trial in Chicago
Not yet recruiting
- Estrogen-receptor-positive Breast Cancer
- +3 more
- elacestrant, palbociclib, abemaciclib, ribociclib
-
Chicago, IllinoisNorthwestern University
Sep 25, 2023
Patterns and Clinical Outcomes of Palbociclib Treated Israel
Completed
- Metastatic Breast Cancer
- palbociclib
-
Herzliya Pituach, IsraelPfizer Pharmaceuticals Israel Ltd.
Jan 20, 2022
Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Tumor Trial in Buffalo (Binimetinib, Palbociclib, Therapeutic
Recruiting
- Colorectal Carcinoma
- +3 more
- Binimetinib
- +2 more
-
Buffalo, New YorkRoswell Park Cancer Institute
May 11, 2022
Breast Cancer Patients Diagnosed With HR+/HER2- Locally Advanced
Active, not recruiting
- Breast Cancer
-
Copenhagen, DenmarkDanish Breast Cancer Group
Jul 6, 2022